Amicus Therapeutics Inc [NASDAQ: FOLD] price plunged by -6.51 percent to reach at -$0.66.
The one-year FOLD stock forecast points to a potential upside of 49.52. The average equity rating for FOLD stock is currently 1.55, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Guru’s Opinion on Amicus Therapeutics Inc [FOLD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FOLD shares is $18.78 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FOLD stock is a recommendation set at 1.55. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Amicus Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on December 19, 2023. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Equal-Weight. The new note on the price target was released on September 09, 2022, representing the official price target for Amicus Therapeutics Inc stock. Previously, the target price had yet another raise to $11, while Goldman analysts kept a Neutral rating on FOLD stock. On January 14, 2022, analysts increased their price target for FOLD shares from 12 to 16.
The Average True Range (ATR) for Amicus Therapeutics Inc is set at 0.39, with the Price to Sales ratio for FOLD stock in the period of the last 12 months amounting to 7.03. The Price to Book ratio for the last quarter was 17.38, with the Price to Cash per share for the same quarter was set at 0.97.
FOLD Stock Performance Analysis:
Amicus Therapeutics Inc [FOLD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.11. With this latest performance, FOLD shares dropped by -15.88% in over the last four-week period, additionally sinking by -19.04% over the last 6 months – not to mention a drop of -22.23% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FOLD stock in for the last two-week period is set at 28.34, with the RSI for the last a single of trading hit 24.08, and the three-weeks RSI is set at 31.62 for Amicus Therapeutics Inc [FOLD]. The present Moving Average for the last 50 days of trading for this stock 11.31, while it was recorded at 10.16 for the last single week of trading, and 12.07 for the last 200 days.
Insight into Amicus Therapeutics Inc Fundamentals:
Amicus Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.52 and a Current Ratio set at 2.88.
Amicus Therapeutics Inc [FOLD] Institutonal Ownership Details
The top three institutional holders of FOLD stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in FOLD stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in FOLD stock with ownership which is approximately 5.8386%.
